Strategic use of biosimilars in cancer care provides an opportunity for more value as these drugs frequently cost less than...
While many payer and provider organizations have found early success with value-based efforts, barriers around data interoperability still prevent the...
The cost of oncology-focused drugs in the U.S. has now exceeded $56 billion and the median annual expense of a new cancer...
Authorizations are among the most manual and costly transactions for health plans and providers alike. Health plans spend a significant...
Approximately 60 percent of U.S. companies are partially or fully self-funding their health plans. With more than a third of...
Technology continues to push the envelope, spurring health care’s continuous evolution. Crises like COVID-19 only reinforce the need for the...
Over the past few months, we’ve seen a fundamental shift in healthcare. With this change comes a host of uncertainty...
NantHealth recently hosted a webinar entitled “The Science Behind Emerging Treatments: A COVID-19 Discussion,” with NantHealth Chief Medical Officer, Dr....
Thursday, May 14 at 12 pm ET NantHealth hosted a live webinar moderated by our Chief Medical Officer, Sandeep ‘Bobby’...
NantHealth recently hosted a webinar entitled “An Evidence-Based Look at Oncology Care in the COVID-19 Pandemic,” with our thought leaders...
Thursday, April 9 at 12 pm ET NantHealth hosted a live webinar with our Chief Medical Officer, Dr. Bobby Reddy,...
While the practice of healthcare continues to make advances in patient care with new research, procedures, and drug therapies, the...
